This protocol includes 2 independent studies. Both studies are multicenter studies, evaluating different therapeutic approaches in two different populations of patients:
* Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments. * Study 2, a minimally invasive interventional study evaluating the results on visual function following reference treatment with intravenous (IV) chemotherapy in association with ophthalmologic or local ophthalmological treatment without IV chemotherapy.
Newly diagnosed retinoblastoma (RB).
Retinoblastoma with at least one eye eligible for conservative management.
Patients likely to be compliant with the study requirements and visits, including late follow-up.
Patients not previously treated with chemotherapy or radiotherapy for this or any other cancer.
Extra-ocular extension of the disease, or
Group E eyes with invasion of the anterior segment, and/or massive tumors of more than 2/3 of the eye.
Patient older than 6 years of age.
Patients with another associated disease contra indicating systemic chemotherapy.
Institut Curie
Lead sponsor
Fondation Rothschild Paris
Collaborator